Premenstrual Dysphoric Disorder
Conditions
Brief summary
Premenstrual dysphoric disorder (PMDD) is a hormone-dependent mental condition that causes significant suffering in 5% of women of reproductive age worldwide. The prominent symptoms are depressed mood, irritability, mood lability and anxiety. Treatment options for PMDD are limited, with 40% non-responders. Deep transcranial magnetic stimulation (dTMS) is a novel therapeutic technique, which is based on modulating neural activity by inducing an electric field in the brain. To date, dTMS was found to be an effective treatment for depression, which is highly comorbid with PMDD. The investigators propose to study the effect of dTMS on PMDD patients in a prospective treatment study.
Detailed description
Premenstrual dysphoric disorder (PMDD) is a hormone-dependent mental condition that causes significant distress in 5% of reproductive age women worldwide. The disorder was recently added to the diagnostic and statistical manual of mental disorders (DSM-5) as one of the mood disorders. PMDD is characterized by affective, cognitive, behavioral, and somatic symptoms. Treatment possibilities are limited, and 30-40% of patients who do not respond to antidepressants or oral contraceptives, are faced with no alternative effective treatment options. PMDD is highly comorbid with major depressive disorder (MDD) and neuroimaging studies in both disorders demonstrate dysfunction of the dorsolateral prefrontal cortex (DLPFC). Deep transcranial magnetic stimulation (dTMS) is a technique of neuromodulation based on specific anatomic induction of an electric field in the brain. To date, dTMS was proved as an effective treatment tool in a number of mental conditions including drug-resistant major depression, in which the onset of the salutary effect of dTMS was relatively quick (compared with conventional antidepressants). Most clinical trials studying the effect of dTMS in major depression, focused on stimulating the DLPFC. The investigators propose to conduct a prospective double blind cross-over study, to study the effect of short-term dTMS treatment on PMDD patients. The aim of this study is to conduct the first evaluation of deep transcranial magnetic stimulation (dTMS) as a treatment option for premenstrual dysphoric disorder (PMDD). The treatment of this recurrent episodic disorder, that effects young, reproductive-age women, poses a significant clinical challenge, as current treatment options imply reproductive impairment (oral contraceptives or GnRH (gonadotropin-releasing hormone) agonists) or disturbing side effects (e.g. sexual side effects in SSRI's (selective serotonin reuptake inhibitor)). In addition, as many as 40% of women with PMDD do not respond to conventional antidepressants or oral contraceptives, and remain without an effective and tolerable treatment option. The symptoms of PMDD are episodic and time-limited, and indeed, some of the pharmacological treatment strategies for PMDD consist of intermittent therapy. Thus, he investigators assume that dTMS administered during the 7-14 symptomatic days (after ovulation), may provide a highly needed, tolerable and efficient treatment option for women suffering from this disorder, and may actually prevent the onset of symptoms.
Interventions
DEVICEdTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil
Patients will undergo 8 sessions of dTMS treatment for two weeks (4 sessions every week).
DEVICESham: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil
Patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week).
Sponsors
Tel-Aviv Sourasky Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
Women at reproductive age (18-50) with a regular menstrual cycle who: 1. Fulfill screening criteria of the premenstrual screening Tool (PSST) for PMDD (Steiner et al., 2003). 2. Report of at least a one year history of regularly experiencing PMDD symptoms, and meet diagnostic criteria for PMDD according to DSM-5 criteria on a clinical psychiatric interview (American Psychiatric Association, 2013). 3. Fulfill criteria for PMDD prospectively, using the daily record of severity of problems (DRSP) (Endicott et al., 2006) for at least two full menstrual cycles of daily symptom charting, by e-mail via a specific software for Internet questionnaires (Qaultrics). A cycle will be considered symptomatic if the luteal phase mean score will be 50% greater than the mean follicular phase score (Endicott et al. 2006). 4. Women receiving oral contraceptives (OC) will be included if usage of OC commenced 3 months prior to their enrollment.
Exclusion criteria
1. Current pregnancy or getting pregnant during the study. 2. Moderate-severe polycystic ovary syndrome 3. Usage of hormonal IUD (intrauterine device) 4. Recent initiation (less than 3 months) of antidepressant pharmacological treatment. 5. Meet axis I DSM-5 diagnosis for a current major depressive episode or a psychotic disorder at admission. 6. Substance dependence or abuse other than nicotine in the 30 days prior to screening. 7. A personal history of seizures or epilepsy, a history of seizures or epilepsy in first degree relatives and the presence of any known factor that can lower the seizure threshold. 8. Previous head injury and the presence of metallic implants in the cephalic region treatment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PMDD symptoms as measured by the PMTS (Premenstrual Tension Syndrome) scales | Patients will be psychiatrically evaluated to assess their mental state and treatment progress throughout the duration of treatments sessions and up to 2 weeks after, an avarage of 6 weeks |
Secondary
| Measure | Time frame |
|---|---|
| PMDD symptoms as measured by DRSP (Daily Record of Severity of Problems) scale | Patients will be psychiatrically evaluated to assess their mental state and treatment progress throughout the duration of treatments sessions and up to 2 weeks after, an avarage of 6 weeks |
Contacts
Primary ContactOren Tene, M.D
Backup ContactAnat Halevy, MBA
Outcome results
None listed